Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (NYSE: A) has awarded the Agilent Thought Leader Award to Professor Gerhardt Attard from University College London for his groundbreaking research in prostate cancer using innovative liquid biopsy technologies. The award will support the identification of biomarkers related to cancer progression through analysis of circulating tumor DNA. Professor Attard expressed excitement about the potential of his research to enhance diagnostic tools for cancer treatment. Agilent's commitment to funding such research highlights its ongoing investment in advancing cancer genomics and diagnostics.
Agilent Technologies (NYSE: A) announced that Stefanos Nikolaidis, an Assistant Professor at USC Viterbi School of Engineering, received the 2022 Early Career Professor Award for his contributions to AI and Machine Vision in manufacturing. This award emphasizes Agilent's commitment to innovative technology in manufacturing, particularly in developing intuitive collaborative robots (cobots). Dr. Nikolaidis' research aims to enhance manufacturing capabilities and ensure timely delivery of high-quality scientific instruments. The company generated $6.32 billion in revenue in fiscal 2021.
Summary not available.
Agilent Technologies (NYSE: A) has been recognized with a Top Project award for its Certified Pre-Owned Instruments Program, which reduces waste significantly. The program allows lab customers to trade in used instruments for cash or new purchases, promoting sustainability. In fiscal 2021, Agilent bought back over 900 used instruments and sold more than 3,500 certified pre-owned instruments. The initiative aligns with Agilent's commitment to net-zero emissions by 2050 and enhances their Environmental, Social and Governance (ESG) efforts.
Agilent Technologies Inc. (NYSE: A) will release its third-quarter financial results for fiscal 2022 after market close on August 16, 2022. A live webcast of the investor conference call will occur at 1:30 p.m. Pacific time on the same day. Agilent is a leader in life sciences and diagnostics, generating $6.32 billion in revenue in fiscal 2021, employing over 17,000 people globally. Investors can access the webcast via the company's investor relations website, with a replay available for 90 days.
Halo Labs, a company specializing in life science instrumentation, has successfully raised $6M in series C financing, led by Agilent Technologies. This funding will be utilized to enhance the commercialization of the Aura™ platform, expand manufacturing capacity, and develop new products targeting pharmaceutical researchers. CEO Rick Gordon expressed that this funding reflects the success of their aggressive growth strategy, noting that their instruments are now widely adopted by major biopharmaceutical firms. The Aura platform combines multiple assays into one instrument, expediting the development of new therapies.
Agilent Technologies Inc. (NYSE: A) has received FDA approval for its content uniformity (CU) testing method utilizing the TRS100 Raman quantitative pharmaceutical analysis system. This approval, which specifically pertains to Teva Pharmaceutical Industries Ltd, marks a significant milestone for Agilent. The TRS100 system facilitates rapid analysis of active pharmaceutical ingredients (API) in tablets or capsules, enhancing quality control processes. The method’s FDA endorsement reduces risks related to adopting this technology, encouraging its implementation in manufacturing and quality control.
Agilent Technologies (NYSE: A) announced that its customer demonstration laboratory in Waldbronn, Germany, achieved the highest level of Green Lab Certification, indicating strong sustainability practices. This certification, recognized by the UN Race to Zero campaign, highlights Agilent's commitment to environmentally friendly operations in energy, water use, and waste management. This facility is the first of its kind for Agilent to receive this certification, with plans for additional labs to follow. The move aligns with Agilent's broader goals of achieving net-zero greenhouse gas emissions by 2050.
Agilent Technologies (NYSE: A) announced its participation in Analytica 2022, taking place from June 21 to 24 in Munich, Germany. The company aims to showcase its latest innovations in mass spectrometry, including AI-driven instruments, which enhance lab productivity. Key products featured include the 6475 Triple Quadrupole LC/MS and 5977C GC/MSD, among others. Agilent emphasizes its commitment to sustainability through products labeled with My Green Lab ACT. Technical experts will be available for consultations at their booths, alongside hosting forum talks throughout the event.
Summary not available.